David Dieter Biography and Net Worth

David Dieter joined Collegium Pharmaceutical in March 2025. Prior to joining Collegium, Mr. Dieter served as Vice President, Legal at Horizon Therapeutics (acquired by Amgen in October 2023), where he managed internal and external legal counsel and served as advisor to executive leadership across business functions including corporate and commercial matters and international expansion. Prior, as Associate General Counsel, Mr. Dieter played a key role in Horizon’s mergers, acquisitions, and dispositions and was instrumental in the 2023 acquisition of Horizon to Amgen. Before Horizon, Mr. Dieter held several leadership roles at Takeda Pharmaceuticals, including Vice President, Government Affairs and Associate General Counsel for Commercial Law. Earlier in his career, Mr. Dieter was a Partner at Freeborn & Peters, a mid-sized, full-service law firm which has since merged with Smith Gambrell Russell, and an Associate at Perkins Coie, a global law firm. He received a B.A. in Economics from the University of Tennessee, Knoxville and a J.D. from the University of Illinois College of Law, Champaign.

What is David Dieter's net worth?: The estimated net worth of David Dieter is at least $2.73 million as of March 18th, 2026. Mr. Dieter owns 77,071 shares of Collegium Pharmaceutical stock worth more than $2,734,864 as of March 23rd. This net worth evaluation does not reflect any other investments that Mr. Dieter may own. Learn More about David Dieter's net worth.
How do I contact David Dieter?: The corporate mailing address for Mr. Dieter and other Collegium Pharmaceutical executives is 100 Technology Center Drive, Stoughton MA, 02072. Collegium Pharmaceutical can also be reached via phone at (781) 713-3699 and via email at [email protected]. Learn More on David Dieter's contact information.
Has David Dieter been buying or selling shares of Collegium Pharmaceutical?: In the last ninety days, David Dieter has sold $488,041.92 in Collegium Pharmaceutical stock. Most recently, David Dieter sold 13,976 shares of the business's stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a transaction totalling $488,041.92. Following the completion of the sale, the executive vice president now directly owns 77,071 shares of the company's stock, valued at $2,691,319.32. Learn More on David Dieter's trading history.
Who are Collegium Pharmaceutical's active insiders?: Collegium Pharmaceutical's insider roster includes Rita Balice-Gordon (Director), Garen Bohlin (Director), Joseph Ciaffoni (CEO), Joseph Ciaffoni (Pres), David Dieter (EVP), Scott Dreyer (EVP), John Freund (Director), Michael Heffernan (Director), Shirley Kuhlmann (EVP), Gino Santini (Director), Thomas Smith (EVP), Colleen Tupper (CFO), and Colleen Tupper (Exec. VP & CFO ). Learn More on Collegium Pharmaceutical's active insiders.
Are insiders buying or selling shares of Collegium Pharmaceutical?: During the last year, insiders at the specialty pharmaceutical company sold shares 11 times. They sold a total of 177,595 shares worth more than $7,029,253.67. The most recent insider tranaction occured on March, 18th when EVP David Dieter sold 13,976 shares worth more than $488,041.92. Insiders at Collegium Pharmaceutical own 2.5% of the company. Learn More about insider trades at Collegium Pharmaceutical.
Information on this page was last updated on 3/18/2026.

David Dieter Insider Trading History at Collegium Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/18/2026	Sell	13,976	$34.92	$488,041.92	77,071

David Dieter Buying and Selling Activity at Collegium Pharmaceutical

Collegium Pharmaceutical Company Overview

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Today's Range

Now: $36.18

$36.46

50 Day Range

MA: $43.26

$34.50

$48.18

2 Week Range

Now: $36.18

$23.23

$50.79

Volume

124 shs

Average Volume

491,633 shs

Market Capitalization

$1.15 billion

P/E Ratio

21.32

Dividend Yield

N/A

Beta

0.67